Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

Table 2

Response to VTD regimen in each group.

Response (, %)	After 8 cycles
	VTD group ()	Improved VTD group ()	value
OR	22 (73.3%)	23 (76.7%)	0.766
CR	4 (13.3%)	3 (10%)	0.688
VGPR	10 (33.3%)	11 (36.7%)	0.787
PR	8 (26.7%)	9 (30%)	0.774
MR	4 (13.3%)	4 (13.3%)	1.000
SD	3 (10%)	3 (10%)	1.000
PD	1 (3.3%)	0	0.313
Not evaluable	0	0	1.000

OR (CR + VGPR + PR): overall response; CR: complete response; VGPR: very good partial response; PR: partial response; MR: minimal response; SD: stable disease; PD: progressive disease; VTD: bortezomib and thalidomide plus dexamethasone.